Low grade endometrial endometrioid adenocarcinoma: A review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features-Reference-Cited by-同舟云学术

Low grade endometrial endometrioid adenocarcinoma: A review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features

Published:2022-05 Issue:3 Volume:39 Page:159-175
ISSN:0740-2570
Container-title:Seminars in Diagnostic Pathology
language:en
Short-container-title:Seminars in Diagnostic Pathology

Author:

Lucas Elena,Carrick Kelley S.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference119 articles.

1. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects;Clement;Adv Anat Pathol,2002

2. Zhang C, Zheng W. High-grade endometrial carcinomas: Morphologic spectrum and molecular classification. Semin Diagn Pathol 2021.

3. Integrated genomic characterization of endometrial carcinoma;Kandoth;Nature,2013

4. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts;Stelloo;Clin Cancer Res,2016

5. A clinically applicable molecular-based classification for endometrial cancers;Talhouk;Br J Cancer,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endometrial Carcinogenesis;Gynecologic and Obstetric Pathology;2024

2. Cervical Cytology Preserves Histologically Detected Surface Epithelial Slackening, Unique to thePOLEMutation-subtype in Endometrial Cancer;In Vivo;2023-12-25

3. Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women;Gynecologic Oncology;2023-10

4. Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists;Cancers;2023-08-15

5. A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data;Cancers;2023-08-08